C ardiovascular diseases result in >600 000 annual deaths in the United States alone, with high blood pressure as a primary or contributing cause to >400 000 of these deaths. 1, 2 Prolonged high blood pressure initially results in concentric pathological hypertrophy, which if left untreated can lead to heart failure with (heart failure with reduced ejection fraction [EF]) or without (heart failure with preserved EF) ventricular dilation and depressed cardiac EF. Both clinical situations also exhibit altered left ventricular (LV) diastolic function that is associated with interstitial fibrosis, decreased LV systolic reserve, increased arterial stiffness, and impaired endothelial function. 3, 4 With sustained disease stress, these structural and functional changes are accompanied by increased cardiomyocyte death from apoptosis and necrosis. Since the heart has little regenerative capacity, 5, 6 myocyte death leads to decreased numbers of functional cardiac myocytes. 7, 8 Current therapies for hypertension and heart failure are somewhat effective but do not reverse many of the disease-induced cardiac alterations. There is a need to identify new therapeutic targets that could slow or reverse adverse cardiac remodeling in acquired cardiovascular diseases, such as hypertension, and especially in heart failure with preserved EF, where there are inadequate therapeutic options. development, and overall tissue homeostasis. This family of proteins is known to be involved in tissue growth and repair but can be dysregulated in cardiovascular disease. 9 Members of this family have diverse roles in the regulation of differentiation, apoptosis, cell migration, adhesion, and extracellular matrix deposition 10 and are being examined as possible therapeutic targets in cardiovascular disease. [11] [12] [13] GDF11 (growth differentiation factor 11) is a member of the TGF-β superfamily of proteins and is highly homologous to the well-studied TGF-β family member, myostatina known negative regulator of skeletal muscle growth. 14, 15 Given its structural similarity to myostatin, GDF11 has been suggested to have a similar effect on skeletal and cardiac muscle. 16 Supporting this idea are recent studies in which circulating GDF11 levels have been increased and result in skeletal and cardiac muscle wasting. 17, 18 These studies documented that overexpression of GDF11 with AAV-2 (adenoassociated virus) infection or with GDF-11-expressing CHO (chinese hamster ovaries) cells resulted in decreases in cardiac and skeletal muscle mass and function and could even induce death of mice at high doses. Interestingly, other studies have shown that GDF11 has little or no effects on cardiac or skeletal muscle mass, 19 and there are some data suggesting that GDF11 treatment can have beneficial effects on the heart. 20, 21 Previous studies on the effects of GDF11 on the normal and diseased heart have produced widely variant findings and conclusions. One series of studies suggested that circulating GDF11 levels decrease with age and that this might cause agerelated pathological cardiac hypertrophy (PCH). When normal GDF11 levels were restored with daily injections of recombinant protein, the aged heart, 22 skeletal muscle, 23 and brain 24 were all rejuvenated. These studies specifically showed that daily injections of GDF11 reversed aging-induced pathological hypertrophy, 22 improved skeletal muscle function, 23 and improved brain vascularization. 24 However, several more recent studies could not validate these results. 19, 25 Our group has shown that the (0.1 mg·kg
) dose of GDF11 reported to reverse aging-induced cardiac pathologies 22 had no effect on cardiac function or structure in aged C57BL/6 mice. 19 No agerelated PCH was observed in these studies. 19 A major purpose of the present study was to bring some clarity to the disparate findings reported about GDF11 effects on the normal and diseased heart in adult mice. In our view, performing studies with recombinant proteins in different laboratories and achieving identical results is clearly challenging, in part because differences in dosing or in the biological activity of the recombinant protein are not easily controlled. These problems might explain some of the disparate results in the literature.
Therefore, to clarify some of the discrepancies in this field, we performed a (blinded) dose-ranging study in which 
Novelty and Significance
What Is Known?
• Age-associated decline in the circulating levels of GDF11 (growth differentiation factor 11) and the acquisition of cardiovascular disease have been linked to pathological hypertrophy and reduced cardiac function in some but not all studies.
• Attempts to increase or restore circulating GDF11 levels with recombinant rGDF11 (recombinant GDF11) have shown either no effects, reversal of pathological processes, or cachexia and premature death.
• It is unclear whether rGDF11 has any significant effect on the structure and function of the normal or diseased heart.
What New Information Does This Article Contribute?
• A broad range of rGDF11 treatments had no significant effects on cardiac structure and function of the normal heart, except at high doses, which were toxic. • An rGDF11 dosage was found that reduced cardiac hypertrophy, dilation, fibrosis, and depressed cardiac function induced by pressure overload.
• High levels of rGDF11 induced severe cachexia and premature death in normal animals, as well as those with pathological cardiac hypertrophy induced by acute pressure overload.
Provocative studies have suggested that age-related reductions in circulating GDF11 levels are responsible for cardiac hypertrophy and abnormal cardiac performance. These results have not been validated, and others have shown that increasing levels of GDF11 can induce body wasting and depressed cardiac function. Because HDF11 has been proposed as an antiaging therapy, it is important to resolve current controversies. We performed a dose-ranging study in normal and pressure overload mice to determine whether rGDF11 had any significant beneficial or harmful effects on the heart and thereby resolve controversies in this field. rGDF11 had no major effects on cardiac structure and function, except at high doses that caused cachexia. Doses of rGDF11 were found that reduced pathological cardiac hypertrophy, prevented ventricular dilation, reduced myocyte size, improved cardiac contractile function, and reduced the interstitial fibrosis associated with diastolic filling defects. Doses of rGDF11 just above those that reduced pathological processes caused by pressure overload severe cachexia and premature death. The high toxicity associated with of high levels of rGDF11 is likely to be a significant limitation for the translation of these findings into a clinical application.
we treated 12-to 13-week-old C57BL6 mice with GDF11 for 14 days, beginning 1 week after undergoing transverse aortic constriction (TAC) or sham surgery. This allowed us to explore dose-dependent GDF11 effects on the structure and function of normal hearts, as well as those with evolving PCH. Our results show that daily injections of GDF11 caused a dose-dependent reduction in body weight (BW) and heart mass in both normal and TAC mice, with a disproportionate decrease in heart weight (HW) in TAC mice. Our results are consistent with the hypothesis that GDF11 can reduce pathological hypertrophy and associated fibrosis in pressure overload. However, we also found that high doses of GDF11 cause cachexia and death. This is consistent with other studies 17, 18, 26 and suggests that GDF11 may cause more harm than good.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. For detailed methods, refer to Materials in the Online Data Supplement.
Briefly, all animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee of Temple University School of Medicine and conducted in accordance with the Guide for the Use and Care of Laboratory Animals. C57BL/6 male mice were purchased at 12 weeks of age from Jackson Laboratories. Mice underwent TAC surgery 1 week before receiving treatment via intraperitoneal injections of 3 doses of GDF11 (0.5, 1.0, and 5.0 mg/kg) or vehicle (60 mM Na Acetate buffer, pH 5.0, and 10% trehalose). Cardiac function before and after TAC surgery was measured by echocardiography using the Vevo2100 ultrasound system. Circulating levels of GDF11, tissue processing, histology, tissue and organ weights, myocardial fibrosis, and hypertrophy were measured in vivo and in vitro as described in the Online Data Supplement. In vitro experiments using mouse embryonic fibroblasts (MEFs) are also described in detail in the Online Data Supplement. Data are represented as mean±SEM. Statistical analysis was performed using linear mixed-effects models, t test, ANOVA with either Dunnet or Tukey multiple comparison tests, Mann-Whitney U test, or Kruskal-Wallis test with Dunn multiple comparisons test. Log, square root, and zero-skewness log-transformations were used to achieve normal distributions.
Results

GDF11 Activates SMAD2 Signaling
The canonical signaling pathway for GDF11 involves activation (phosphorylation) of SMAD2/3. GDF11 injections caused a 5.72-, 6.41-, and 11.03-fold increase in the circulating plasma concentrations of GDF11 in the 0.5, 1.0, and 5.0 mg/kg treated sham animals, respectively, compared with the vehicle-treated sham animals, whereas the plasma concentrations increased 7.19-, 7.97-, and 13.90-fold for the 0.5, 1.0, and 5.0 mg/kg treated TAC animals, respectively ( Figure 1A) . Treatment with 5.0 mg/kg of GDF11 significantly increased SMAD2 phosphorylation in Sham animals, and TAC significantly increased phosphorylation of SMAD2 compared with vehicle-treated sham mice, whereas treatment with GDF11 further increased SMAD2 phosphorylation in TAC mice, although this did not reach statistical significance ( Figure 1B and 1C). Treatment with 5.0 mg/kg of GDF11 significantly decreased total SMAD2 expression in both TAC and sham animals. We also measured SMAD3 phosphorylation and found a similar trend for increased SMAD3 phosphorylation and decreased total SMAD3 expression (Online Figure I) .
These results support the idea that GDF11 treatment causes a dose-dependent activation of SMAD signaling in normal and hypertrophied heart.
GDF11 Decreases TAC-Induced Cardiac Hypertrophy
Pulsed wave Doppler-based echocardiography techniques were used 1 week after sham or TAC surgery to determine the peak pressure gradient across the aortic constriction. TAC caused a significant increase in the peak pressure gradient across the constriction in TAC mice ( Figure 2A) . TAC mice were then randomized to either GDF11 or vehicle treatment groups so that there were no significant differences in the peak pressure gradients at the time of initial treatment ( Figure 2A ). Three weeks of TAC (without GDF11 treatment) caused significant cardiac hypertrophy as evidenced by increases in HW (Online Table I Table I ), BW (Online Table I Table I ), BW (Online Table I ), HW/TL ( Figure 2C ), echocardiography-derived cardiac mass and dimensions ( Figure 4C and 4D), and myocyte CSA ( Figure 3B ). There was no significant effect of 5.0 mg/ kg GDF11 on HW/BW in sham mice ( Figure 2B ). Sham mice treated with 5.0 mg/kg GDF11 showed signs of severe cachexia (see below) and either died or had to be euthanized 10 to 11 days after GDF11 treatment.
GDF11 treatment at some doses reduced cardiac hypertrophy. In TAC mice, the lowest GDF11 dose (0.5 mg/kg) had no significant effect on BW, HW, and echocardiographyderived ventricular wall thicknesses and mass. However, a small but significant decrease in the LV internal dimension was found at 3 weeks compared with the vehicle-treated TAC mice. The 1.0 mg/kg GDF11 dose caused a significant reduction in HW and HW/TL (Online Table I ; Figure 2C ) and myocyte CSA ( Figure 3B ). The highest GDF11 dose (5.0 mg/kg) caused significant reductions in HW (Online Table I ) BW, HW/TL ( Figure 2C ), and echocardiography-derived LV wall thicknesses, dimensions, and cardiac mass ( Figure 4A and 4D) compared with the measurements taken at 1 week, before the start of treatment. The 5.0 mg/kg dose also caused a significant reduction in these parameters, with the exception of LV posterior wall thickness, at 3 weeks compared with the vehicle-treated TAC mice. GDF11 caused significant reductions in myocyte CSA in TAC mice with CSA regressing to almost normal levels at the 1.0 mg/kg-a dose that did not induce cachexia ( Figure 3B ). Classical hypertrophy markers (brain natriuretic peptide, α-and β-MHC, and ACTA1 [α-skeletal actin]) were significantly altered in TAC versus sham vehicle-treated animals ( Figure 3C and 3F). GDF11 treatment had no significant effects on the mRNA for these markers, except at the highest GDF11 dose that caused cachexia. Like sham mice, TAC mice treated with 5.0 mg/kg GDF11 showed signs of severe cachexia, were lethargic, and needed to be euthanized 9 to 10 days after treatment was initiated.
These findings show that GDF11 induces a dose-dependent decrease in PCH but at high GDF11 doses (5.0 mg/kg) also induces a body-wasting phenotype (see below) that can become so severe that mice either died or had to be euthanized because they lost in excess of 30% of their BW within 9 to 10 days of treatment (Online Figure IB) .
GDF11 Improves Cardiac Structure and Function
Echocardiography was used to determine time-dependent changes in cardiac structure and function in sham and TAC mice treated with vehicle or GDF11. In vehicle-treated TAC mice, the LV began to dilate, and pump function began to decline by week 3 post-TAC with significant decreases in EF and fractional shortening and an increase in end-systolic and end-diastolic LV volumes ( Figure 5A through 5C ). TAC mice treated with 0.5 mg/kg of GDF11 experienced similar decreases in EF and fractional shortening ( Figure 5A and 5B) but experienced no dilation ( Figure 4C ). However, TAC mice treated with 1.0 mg/kg of GDF11 exhibited a modest increase in EF and fractional shortening and dilation was not present. About 5.0 mg/kg of GDF11 caused a significant increase in EF and fractional shortening in TAC mice between weeks 1 and 3 post-TAC ( Figure 5A and 5B). Sham mice treated with Figure 1 . Injections of rGDF11 (recombinant growth development factor 11) increase the circulating concentration of GDF11 (growth development factor 11) and SMAD2 protein phosphorylation. A, Plasma was collected 1 to 1.5 h after injection of GDF11 or vehicle. B, Log-transformations of ratio of phosphorylated (p) to total (T) forms of SMAD2 protein, as well as the ratio of phosphorylated (p) to total (T) SMAD2 to GAPDH (glyceraldehyde 3-phosphate dehydrogenase) in the hearts of vehicle-treated and GDF11-treated transverse aortic constriction (TAC) and sham mice was quantified by densitometry (n=5-8 per group). C, Immunoblotting for phosphorylated (p) and total (T) forms of SMAD2 and GAPDH protein expression in the hearts of vehicle-treated and GDF11-treated TAC and sham mice. *P<0.05 vs vehicle-treated TAC mice. #P<0.05 vs vehicle-treated sham mice. t tests: TAC vehicle vs sham vehicle, sham vehicle vs sham 5.0 mg/kg 1-way ANOVA using Dunnet multiple comparison test: TAC animals.
Circulation Research
November 9, 2018 the 5.0 mg/kg dose also experienced an increase in EF, but this was not significant. End-systolic and end-diastolic volumes were unchanged in the 0.5 and 1.0 mg/kg treated TAC mice between weeks 1 and 3 post-TAC, whereas these volumes significantly decreased in the 5.0 mg/kg treated sham and TAC mice ( Figure 5C and 5D). End-diastolic and end-systolic volumes were significantly smaller at 3 weeks in both 0.5 and 1.0 mg/kg treated compared with the vehicle-treated TAC animals. These results show that GDF11 treatment in TAC mice can prevent cardiac dilation and progressive depression of cardiac pump function.
GDF11 Decreased Cardiac Fibrosis In Vivo but Activates MEFs
PCH induced by pressure overload is associated with increased cardiac fibrosis. [27] [28] [29] In the present experiments, TAC significantly increased both perivascular and interstitial cardiac fibrosis in vehicle-treated TAC versus sham mice ( Figure 6A through 6C). GDF11 treatment of sham mice had no effect on the small amount of observed cardiac fibrosis, even at high GDF11 doses. In TAC mice, the 1.0 mg/kg dose of GDF11 caused significant decreases in interstitial fibrosis but had no significant effect on perivascular fibrosis (Figure 6A through 6C) . Reverse transcription polymerase chain reaction analysis of Col1a1 (collagen, type I, α1) showed a significant increase in Col1a1 mRNA abundance after TAC and a trend for a dose-dependent reduction in Col1a1 abundance in GDF11-treated TAC mice treated with the 1.0 and 5.0 mg/kg doses ( Figure 6D ). MMP (matrix metalloproteinase) expression was measured in cardiac tissue homogenates. No differences were found between the vehicle TAC and 1.0 mg/kg TAC in any of the MMPs measured (Online Figure III) . Cytokine expression was also measured in these tissue homogenates, as well as in the plasma collected 3 weeks after TAC surgery. Several of the cytokines were below the limit of detection in all groups tested, and no significant differences were found in the tissue homogenate samples. Similar results were found with plasma samples, but the 5.0 mg/kg treatment group showed a significant increase in the expression of MCP-1 and TNF-α, which are proinflammatory cytokines shown to be increased in cancer cachexia. 30 Interestingly, IL (interleukin)-10-an anti-inflammatory cytokine-was also increased in the 5.0 mg/kg treated TAC animals.
We also explored the idea that GDF11 has direct antifibrotic effects on fibroblasts. We used MEFs treated with 5 nmol/L GDF11, 50 nmol/L GDF11, 10 ng/mL of TGF-β, or TGF-β treatment for 24 hours followed by either 5 or 50 nmol/L GDF11. RNA was extracted, and cells were also fixed and stained for α-SMA (α-smooth muscle actin) and vimentin after 72 hours of treatment with TGF-β/GDF11. We found that GDF11 significantly increased the expression of positively stained α-SMA positive MEFs but to a lesser extent than TGF-β treatment alone or the combination of TGF-β followed by GDF11 ( Figure 7A and 7B) . We observed similar results using polymerase chain reaction. GDF11 increased col1a1 and periostin mRNA but not to the extent seen with TGF-β treatment ( Figure 7C through 7E) . GDF11 treatment caused no changes in the abundance of these factors in TGF-β-treated MEFs ( Figure 7C through 7E) 
High Doses of GDF11 Cause Cachexia
Both sham and TAC mice receiving a 5.0-mg/kg dose of GDF11 lost ≈30% of their BW within 9 days of treatment Table II) . Three weeks of pressure overload had no effect on BW or skeletal muscle ( Figure 8B ) and organ weights (Online Figure VII) . Treatment with 0.5 and 1.0 mg/kg of GDF11 also had no significant effect on the weight of these tissues. However, sham and TAC mice treated with the 5.0-mg/kg dose of GDF11 had decreased tibialis anterior, quadriceps, and gastrocnemius weights, as well as decreases in liver, kidney, and spleen weights (Online Figure VIIB) . Lung weight was unaffected (Online Table I ). Reverse transcription polymerase chain reaction analysis of genes involved in atrophy and proteasome degradation showed an increase in the mRNA expressions of Bnip3, Bnip3L, Trim63, and Fbxo32 in mice treated with 5.0 mg/kg GDF11, with no significant difference between the 1.0 mg/kg and vehicle-treated mice ( Figure 8C ) These results show that high doses of GDF11 cause severe body wasting and can cause death.
Discussion
PCH is a consequence of multiple cardiovascular diseases and is a major cause of morbidity and mortality. 31 There is an unmet clinical need for novel therapeutic strategies to reduce PCH and thereby improve the quality and duration of patients' lives. Recent studies 22, 32 have suggested that GDF11 is a natural, circulating, anti-PCH factor. GDF11 levels in the blood may decrease with aging, and this decrease has been associated with the emergence of pathological hypertrophy. 22 A single study suggests that restoring normal GDF11 levels in old mice reverses PCH, 22 consistent with a natural antihypertrophic effect. However, the beneficial effects of GDF11 in old mice have not been routinely confirmed, 19 and there is evidence that excess GDF11 levels have severe adverse effects, 17, 18 including severe cachexia and death, that could obviously preclude its usefulness as a therapeutic.
The purpose of this study was to determine dose-dependent effects of circulating rGDF11 on cardiac structure and function in normal healthy mice, as well as in mice with PCH induced by TAC. A dose-ranging study was performed because the literature suggests that much of the current controversy about possible beneficial or adverse GDF11 effects results from different GDF11 dosing, 33 poorly characterized rGDF11, 21 and the difficulty in reliably measuring blood levels of biologically active GDF11. 34, 35 In this regard, it was previously suggested that a GDF11 treatment dose of 0.1 mg·kg −1 ·day −1 was sufficient to reverse aging-induced PCH but had no effect on TAC-induced PCH. 22 Our group was unable to confirm that old mice actually had any age-related PCH, and we could not find any PCH reversal with this GDF11 dose (0.1 mg/kg). 19 In subsequent studies, others showed that GDF11 doses of 0.5 and 1.0 mg/kg reduced HW/BW ratios in normal young and aged mice, as well as myocyte CSA, 21 suggestive of a body-wasting phenotype. A major goal of the present study was to determine whether an anti-PCH effect of GDF11 could be separated from its ability to cause skeletal muscle wasting.
17,18
GDF11 Reduces PCH and Improves Cardiac Structure and Function
In the present study, PCH induced by TAC was produced in normal, young mice. After PCH was confirmed (1 week after surgical induction), mice were then randomized to different treatment groups for a dose-ranging study in which mice were treated with intraperitoneal injections of GDF11 (0.5, 1.0, and 5.0 mg·kg
) or vehicle for ≤14 days. At the completion of the study, we tested the plasma for increases in the circulating concentration of GDF11 and the heart for evidence of Smad2 and Smad3 phosphorylation. Although the increases were variable and thus not significant, these experiments suggest that daily injections of GDF11 increased the circulating blood concentrations of GDF11 and activated the canonical GDF11 signaling pathway in the heart ( Figure 1B and 1C) .
A previous study showed that 10 intraperitoneal injections of GDF11 at 1.0 mg/kg caused a decrease in both HW/BW ratio and myocyte CSA in noninjured young and old mice. 21 These findings suggest that GDF11 might reduce cardiac size, but the cause is not entirely clear. Our study showed no significant reductions in myocyte CSA at all GDF11 doses in sham mice, consistent with previously published results showing that treatment of normal animals with 0.5 and 1.0 mg/kg of GDF11 had no significant effect on their HW, BW, HW/ BW, or HW/TL ratios. There were small reductions in HW and BW at the 1.0-mg/kg dose, but they were not significantly different than in untreated animals. Importantly, the highest GDF11 dose (5 mg/kg) tested indeed caused profound reductions in both body and HW, but again, there was not a significant reduction in HW/BW. The fact that HW/BW changes were not induced in normal (sham) animals suggests to us that the primary dose-dependent effect of GDF11 was to reduce lean body mass, and heart size was then reduced as a function of its changing work demands. There was a decrease in the HW/TL in the 5.0-mg/kg treated sham mice because the TL remained unchanged.
In mice with TAC-induced PCH, GDF11 treatment resulted in a dose-related decrease in HW/BW ratio which reached significance in the 5.0-mg/kg treatment group and a significant decrease in HW/TL at both the 1.0-and 5.0-mg/kg doses. However, only the 5.0-mg/kg GDF11 dose caused a significant reduction in BW with lethargy and overall body wasting (see below). A dose-dependent decrease in the myocyte CSA was observed in TAC mice treated with GDF11, which was significant at 1.0 and 5.0 mg/kg ( Figure 3A and 3B) , and a dose-dependent decrease in the LV mass was also observed in the GDF11-treated TAC mice ( Figure 4D) .
A previous report suggested that GDF11 does not reduce TAC-induced hypertrophy. 22 This study 22 used a low GDF11 dose of 0.1 mg·kg −1 ·day −1 and did not test a range of GDF11 levels. In the present experiments, we found clear evidence that GDF11 can cause dose-dependent reductions in PCH at both the heart and myocyte level. Our studies used a range of GDF11 doses that went from low doses that cause little or no changes in normal or TAC-induced cardiac structure and function to high doses that caused severe cachexia and premature death. Within this dosing range (1.0 mg/kg), we observed reductions in TAC-induced cardiac (and cardiac myocyte) size without major changes in BW. The broad range of GDF11 doses we used could explain the differences between ours and other related GDF11 studies. Overall, we observed antihypertrophic effects that were best observed at our 1.0 mg·kg −1 ·day −1 dose of GDF11. Larger effects were seen at our highest dose (5.0 mg·kg −1 ·day −1 ), but interpretation of these effects is 
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complicated by the severe cachexia that was also induced. The reduction in HW/BW and myocyte CSA toward sham levels in TAC animals that was caused by GDF11 suggests to us that it can blunt PCH.
The highest GDF11 dose tested (5.0 mg·kg
) caused severe muscle (and other organ/tissue) wasting (>30% loss of BW in 9 days) in both normal and TAC mice that caused death or severe lethargy that forced us to euthanize the mice. In the TAC mice, the-5.0 mg/kg treatment caused significant reductions in LV wall thicknesses and internal dimensions compared with the vehicle-treated TAC mice, with the walls returning to baseline thickness and the LV internal dimension decreasing. These results are similar to those reported by others. 17, 18 GDF11 treatment of TAC mice increased cardiac systolic function, as measured by echocardiography and reduced dysfunctional ventricular remodeling (ventricular dilation). These results support some but conflict with findings in other studies. 18 One study reported that mice injected with GDF11 secreting CHO cells had reduced cardiac size but also reduced systolic function. 18 In our experiments, echocardiographyderived systolic function decreased significantly between baseline and 3 weeks in vehicle-treated TAC mice, and the LV chamber began to dilate ( Figure 4C) , consistent with the timedependent changes in cardiac structure and function that are a prelude to heart failure in this animal model. 36, 37 A major finding of the present study is that GDF11 treatment prevented or reversed these structural and functional changes (Figures 4A through 4D and 5A through 5D), albeit over a narrow dosing range and for a short time period. Collectively, these results suggest that there is an rGDF11 dose range that can reverse the progression of PCH and improve cardiac function without causing cachexia. Future studies could explore the durability of these effects.
GDF11 Reduces TAC-Induced Interstitial Fibrosis
TAC induced significant increases in cardiac interstitial and perivascular fibrosis ( Figure 6A and 6B) . This has been shown in many previous studies. 29, [38] [39] [40] [41] Members of the TGF-β family of proteins are thought to be involved in pathological cardiac fibrosis.
12,42,43 Surprisingly, we found a rGDF11-dependent decrease in interstitial fibrosis in the TAC mice, although this was only significant in the 1.0-mg/kg treated animals ( Figure 6A and 6B) . We examined the direct effects of GDF11 and TGF-β on MEFs. These studies (Figure 7) showed that 48 hours of treatment with GDF11 and TGF-β increased the gene expression of acta2, col1a1, and postn. The effects of GDF11 were smaller than those of TGF-β, and GDF11 did not change the properties of TGF-β-exposed MEFs. GDF11 treatment for 72 hours increased the percentage of MEFs expressing α-SMA protein. These findings showed that GDF11 has no significant effects on TGF-β-induced changes in MEF properties. These results are similar to our previous findings in which GDF11 increased fibronectin expression in human dermal fibroblasts. 19 The results in MEFs do not explain our in vivo findings in which mice treated with GDF11 had less interstitial fibrosis than vehicle-treated TAC mice, suggesting that our antifibrotic GDF11 effects are not because of direct effects of GDF11 on cardiac fibroblasts. We also tested cytokine expression levels in the heart and plasma and MMP expression levels in the plasma (Online Figures IV through  VI) . No differences in these levels were observed in either the plasma or the tissue at the time points assessed. It is likely that the antifibrotic effects observed in our in vivo studies involve multiple factors independent of direct effects on fibroblasts. Although we were unable to detect differences in cytokine expression at the time point we assessed (3 weeks after TAC surgery), it is still possible that GDF11 may play a role in modulation of the immune cells that invade hearts with PCH. It has been shown that immune cell infiltration and cytokine expression is increased by 7 days but returns to baseline by 28 days during pressure overload. 29 
High GDF11 Treatment Doses Cause Cachexia and Death
The primary goal of our study was to test potential anti-PCH effects of circulating GDF11. We used rGDF11 to explore this idea. The most common method for treatment with rGDF11 is daily intraperitoneal injections. 19, 20, [22] [23] [24] [25] 44 At the lowest doses used, 0.5 and 1.0 mg·kg
, we saw no apparent negative noncardiac effects of GDF11 in either sham or TAC mice (Figure 8B and 8C; Online Figure VII) . However, mice treated with the highest dose tested, 5.0 mg/kg, experienced severe cachexia and had to be euthanized within 10 days of treatment because of severe weight loss and lethargy in every treated mouse and the death of a few mice. The cachexic effects of GDF11 have been reported previously 17, 18 and were not surprising. GDF11 is highly homologous to another TGF-β family member, myostatin. Myostatin activates the canonical SMAD2/3 pathway to negatively regulate skeletal muscle growth. 45, 46 The cachexia seen in our study at high GDF11 doses is likely because of mechanisms recently defined by others. 26 We also observed an increase in the gene expression of Bnip3, Bnip3L, Trim63, and Fbxo32, which are involved in cell death and the ubiquitin ligase pathway in mice treated with 5.0 mg/kg GDF11, whereas there were no differences between the 1.0-mg/kg and vehicle-treated mice. Our results clearly show that high levels of circulating GDF11 mimic the skeletal muscle atrophy effects of high levels of myostatin.
Our study documents that GDF11 can cause dose-dependent reduction in PCH and cardiac fibrosis. One caution is comparing our dosing with those in other studies. [21] [22] [23] [24] [25] Differences in bioactivity of the rGDF11 used could make these comparisons dangerous. It was for this reason that we used a broad range of rGDF11 doses in the present experiments. Our results with this approach support the idea that increasing circulating GDF11 levels can reduce PCH, improve cardiac structure and function, and reduce pressure overload-induced cardiac fibrosis. Olson et al 32 found that higher concentrations of circulating GDF11 were associated with less LV hypertrophy in patients from the Heart and Soul and HUNT3 (Nord-Trondelag Health Study) studies, as well as a lower adjusted risk for cardiovascular events or deaths. It is difficult to compare circulating levels of GDF11 measured in our study to the levels reported in humans under physiological or pathological states because of difficulties in detecting the protein in the circulation and differing methods used. Schafer et al 34 determined the circulating levels of GDF11 in healthy adults to be around 0.4 to 0.6 ng/mL and found that GDF11 levels did not change with age in the population they examined. Another study examining the serum levels of GDF11 in hemodialysis patients found GDF11 to be 9.4±5.1 compared with 7.3±5.9 pg/mL in agematched healthy controls. 47 However, all of these studies used different methods to quantify circulating levels of GDF11, and the technique used by Olson et al 32 also detected myostatin and did not separate the actual concentrations of GDF11. Our results showed variability within treatment groups for the November 9, 2018 concentration of GDF11 in the plasma of the animals after injection, with an overall increase in blood levels with GDF11 treatment dose. With the approaches we developed, we measured concentrations in the range of 1 to 500 ng/mL depending on the treatment dose. Until reliable techniques for measuring GDF11 are validated, comparisons between studies should be done cautiously. Our study with high levels of GDF11 resulted in increased circulating GDF11 and caused negative effects on the skeletal muscle and organs. Our range of dosing was broad, and, therefore, the threshold dose of GDF11 at which mice would begin to experience the negative effects was not clearly defined. Our study shows that any clinical application of a GDF11 treatment strategy could have devastating effects on the heart, skeletal muscle, and other organs.
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